ErbB2-positive Mammary Tumors Can Escape PI3K-p110α Loss Through Downregulation of the Pten Tumor Suppressor

A M Simond,T Rao,D Zuo,J,W J Muller

DOI: https://doi.org/10.1038/onc.2017.264

IF: 8.756

2017-01-01

Oncogene

Abstract:Breast cancer is the most common cancer among women and 30% of patients will be diagnosed with an ErbB2-positive tumor. Forty percent of ErbB2-positive breast tumors have an activating mutation in p110α, a catalytic subunit of phosphoinositide 3-kinase. Clinical and experimental data show that breast tumors treated with a p110α-specific inhibitor often circumvent inhibition and resume growth. To understand this mechanism of resistance, we crossed a p110α conditional (p110α flx/flx ) mouse model with mice that overexpress the ErbB2/Neu-IRES-Cre transgene (NIC) specifically in the mammary epithelium. Although mammary-specific deletion of p110α dramatically delays tumor onset, tumors eventually arise and are dependent on p110β. Through biochemical analyses we find that a proportion of p110α-deficient tumors (23%) display downregulation of the Pten tumor suppressor. We further demonstrate that loss of one allele of PTEN is sufficient to shift isoform dependency from p110α to p110β in vivo . These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110α inhibition.